Shots:
Gilead signed a research partnership with Kymera to develop an oral molecular glue degrader (MGD) targeting cyclin-dependent kinase 2 (CDK2) for the treatment of breast cancer and other solid tumors
Kymera will receive a total of up to $85M in upfront and option exercise payments and is eligible for up to $665M, plus high…
